186 related articles for article (PubMed ID: 8616823)
1. Overexpression of her-2/neu in human prostate cancer and benign hyperplasia.
Gu K; Mes-Masson AM; Gauthier J; Saad F
Cancer Lett; 1996 Feb; 99(2):185-9. PubMed ID: 8616823
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of topoisomerase II alpha and Her-2/neu in prostatic carcinoma and benign prostatic hyperplasia.
Hasby EA; Saied EM
J Egypt Natl Canc Inst; 2008 Jun; 20(2):158-67. PubMed ID: 20029472
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer.
Sadasivan R; Morgan R; Jennings S; Austenfeld M; Van Veldhuizen P; Stephens R; Noble M
J Urol; 1993 Jul; 150(1):126-31. PubMed ID: 7685420
[TBL] [Abstract][Full Text] [Related]
4. HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization.
Ross JS; Sheehan C; Hayner-Buchan AM; Ambros RA; Kallakury BV; Kaufman R; Fisher HA; Muraca PJ
Hum Pathol; 1997 Jul; 28(7):827-33. PubMed ID: 9224752
[TBL] [Abstract][Full Text] [Related]
5. Expression of c-erb B-2/neu proto-oncogene in human prostatic cancer tissues and cell lines.
Zhau HE; Wan DS; Zhou J; Miller GJ; von Eschenbach AC
Mol Carcinog; 1992; 5(4):320-7. PubMed ID: 1353965
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology.
Sanchez KM; Sweeney CJ; Mass R; Koch MO; Eckert GJ; Geary WA; Baldridge LA; Zhang S; Eble JN; Cheng L
Cancer; 2002 Oct; 95(8):1650-5. PubMed ID: 12365012
[TBL] [Abstract][Full Text] [Related]
7. Differential immunoreactivity of her-2/neu oncoprotein in prostatic tissues.
Ibrahim GK; MacDonald JA; Kerns BJ; Ibrahim SN; Humphrey PA; Robertson CN
Surg Oncol; 1992 Apr; 1(2):151-5. PubMed ID: 1285216
[TBL] [Abstract][Full Text] [Related]
8. Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma.
Kuhn EJ; Kurnot RA; Sesterhenn IA; Chang EH; Moul JW
J Urol; 1993 Nov; 150(5 Pt 1):1427-33. PubMed ID: 8105108
[TBL] [Abstract][Full Text] [Related]
9. Expression of NEU/HER-2 oncoprotein (p185neu) in prostate tumors: an immunohistochemical study.
Giri DK; Wadhwa SN; Upadhaya SN; Talwar GP
Prostate; 1993; 23(4):329-36. PubMed ID: 7505056
[TBL] [Abstract][Full Text] [Related]
10. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays.
Wang S; Saboorian MH; Frenkel E; Hynan L; Gokaslan ST; Ashfaq R
J Clin Pathol; 2000 May; 53(5):374-81. PubMed ID: 10889820
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of HER-2/neu in patients with prostatic adenocarcinoma.
Zahir ST; Tafti HF; Rahmani K
Asian Pac J Cancer Prev; 2014; 15(15):6425-8. PubMed ID: 25124637
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma.
Ross JS; Sheehan CE; Hayner-Buchan AM; Ambros RA; Kallakury BV; Kaufman RP; Fisher HA; Rifkin MD; Muraca PJ
Cancer; 1997 Jun; 79(11):2162-70. PubMed ID: 9179063
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of interleukin-2 receptor and interleukin-6 in patients with prostate cancer and benign prostatic hyperplasia: association with asymptomatic inflammatory prostatitis NIH category IV.
Engelhardt PF; Seklehner S; Brustmann H; Lusuardi L; Riedl CR
Scand J Urol; 2015 Apr; 49(2):120-6. PubMed ID: 25363611
[TBL] [Abstract][Full Text] [Related]
14. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
[TBL] [Abstract][Full Text] [Related]
15. Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer.
Liao Y; Grobholz R; Abel U; Trojan L; Michel MS; Angel P; Mayer D
Int J Cancer; 2003 Nov; 107(4):676-80. PubMed ID: 14520710
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence.
Velasco A; Hewitt SM; Albert PS; Hossein M; Rosenberg H; Martinez C; Sagalowsky AI; McConnell JD; Marston W; Leach FS
Cancer; 2002 Feb; 94(3):690-9. PubMed ID: 11857301
[TBL] [Abstract][Full Text] [Related]
17. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer.
Osman I; Scher HI; Drobnjak M; Verbel D; Morris M; Agus D; Ross JS; Cordon-Cardo C
Clin Cancer Res; 2001 Sep; 7(9):2643-7. PubMed ID: 11555574
[TBL] [Abstract][Full Text] [Related]
18. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
[TBL] [Abstract][Full Text] [Related]
19. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.
Liu HL; Gandour-Edwards R; Lara PN; de Vere White R; LaSalle JM
Cancer J; 2001; 7(5):395-403. PubMed ID: 11693898
[TBL] [Abstract][Full Text] [Related]
20. [Expression of the cerbB-2 (HER-2/neu) oncoprotein in prostatic adenocarcinoma].
San Miguel Fraile P; Dos Santos JE; Pélaez Boismorand E; Ortiz Rey JA; Iglesias Rodríguez B; Cambronero Santos J; Fajardo Seijo JL; Rodríguez Costas JM; Fernández Regueiro M
Actas Urol Esp; 2005 Jan; 29(1):64-9. PubMed ID: 15786765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]